Member Info for Chelsea11

Hi EE.

According to Peel Hunt, 32pc of AIM companies with a market cap of £50m to £250m have seen their share price fall by more than 30pc in the last 12 months leaving them ripe for an approach from a buyer next year.”

“I have little doubt that Scancell is firmly in that group”

However Scancell are not in that group are they, hard evidenced by the fact that the SP now, is roughly the same as it was 12 months ago.

“ Someone else is likely to reap the benefit of decades of scientific advance and hard work”

Not necessarily.

Balerno - that was never a communicated deadline.

Apparently it only works if washed down with half a litre of bootleg Smirnoff…..

https://youtu.be/m8LxclIZ96I?feature=shared

Ramsdens intends to announce its FY24 results on 14 January 2025.

Just a month away now. Gold prices have remained at / near record levels. Current climate suggests pawnbroking arm will have been busy. Christmas period for jewellery sales.

I’m hopeful of seeing 250p in Q1.

Matt - they were only ever research / pre-clinical investigation agreements. AFAIK, no company names were ever disclosed, nor granular details of the agreements. Did it all fade away? Given 4+ years have passed, I’m not expecting anything that would now be a catalyst to the SP but see those agreements as a typical evolution of a small Bio. SCLP has certainly evolved in a positive way since those historic announcements.

I guess rather than an outright sale, there could be a spin-off arrangement made, whether that be 100%, or something like 80%/20%. That may suit the ambitions & objectives of both companies.

Pie in the sky of course but positive we’re even in a position to mull it over in association with a player like Genmab.

Don’t know what you’re on about Bojo.

I’m not dragging anyone into the convo and simply stated that it had been pointed out to Cleaner, that SCLP were not included in the Economist article.

“ Go crawl back under your own stone.. without leaving a slimy trail”

And I’m the one being accused of getting personal?

Indeed Bojo and it took one of those two posters you mention, to earlier today squash the inference made that SCLP had been mentioned in an Economist article!

Violin - firstly I didn’t name any poster, nor did I suggest my post was aimed exclusively at one poster in particular. You have made that assumption all on your own.

As for turning over every stone. That’s fine if what you find under them is truly relevant and you are prepared to add intelligence & context around why you believe it is.

Recs would evidence others share my view.

I believe one of the biggest issues for the BB is that at times, there is a total blizzard of information, much of which has no direct connection to Scancell at all, even though sometimes there is heavy inference simply by being posted, that there is. It is clear that often, the poster doesn’t even understand what they are posting, hence no effort made to add any accompanying context. On occasion, this info is then repeated & recycled, adding only more fog & confusion and no investor value at all.

Just my view and sure I’m not alone.

Yes. What I was explaining previously. Choosing to use/pay for a platform that provides a full service when you need it, or using one that doesn’t and risk losing out.

Share price up over last 12 months.

Clinical trials progressing.

Data building and currently exceeding endpoints.

Commercial deals made.

I’m cool for 2025.

Https://www.proactiveinvestors.co.uk/companies/news/1062486/begbies-traynor-jumps-as-increasing-insolvencies-boosts-profits-1062486.html

Cleaner - do you work for Genmab?

What the update does categorically confirm (yet again) though, is that those here who have in the past continuously bleated that there is “little growth” and “acquisitions are a distraction”, are talking total bobbins.

Ciaskin - yes

May as well be the Genmab BB.

Harry - you buy carp, you should expect carp.

That’s not wise, it’s the law.

A consequence really of electing to use an inferior platform with terrible reviews.